Gene expression profiling of mononuclear cells from patients with sepsis secondary to community-acquired pneumonia  by Severino, Patricia et al.
Genomics Data 2 (2014) 332–334
Contents lists available at ScienceDirect
Genomics Data
j ou rna l homepage: ht tp : / /www. journa ls .e lsev ie r .com/genomics-data /Data in BriefGene expression proﬁling of mononuclear cells from patients with sepsis
secondary to community-acquired pneumoniaPatricia Severino a,⁎, Eliezer Silva b, Giovana Lotici Baggio-Zappia c, Milena Karina Colo Brunialti c,
Laura Alejandra Nucci c, Otelo Rigato Junior d, Ismael Dale Cotrim Guerreiro da Silva e,
Flavia Ribeiro Machado f, Reinaldo Salomao c
a Center for Experimental Research, Instituto Israelita de Ensino e Pesquisa, Hospital Israelita Albert Einstein, Sao Paulo, Brazil
b Intensive Care Unit, Hospital Israelita Albert Einstein, Sao Paulo, Brazil
c Division of Infectious Diseases, Escola Paulista de Medicina, Universidade Federal de Sao Paulo, Sao Paulo, Brazil
d Intensive Care Unit, Hospital Sirio Libanes, Sao Paulo, Brazil
e Department of Gynecology, Escola Paulista de Medicina, Universidade Federal de Sao Paulo, Sao Paulo, Brazil
f Intensive Care Unit, Hospital Sao Paulo, Universidade Federal de Sao Paulo, Sao Paulo, Brazil⁎ Corresponding author.
E-mail address: patricia.severino@einstein.br (P. Sever
http://dx.doi.org/10.1016/j.gdata.2014.10.004
2213-5960/© 2014 The Authors. Published by Elsevier Inca b s t r a c ta r t i c l e i n f oArticle history:
Received 30 September 2014
Accepted 2 October 2014
Available online 12 October 2014
Keywords:
Sepsis
Gene expression proﬁling
DNA microarray
Patient outcomeMechanisms governing the inﬂammatory response during sepsis involve crosstalk between diverse signaling
pathways, but current knowledge provides an incomplete picture of the syndrome.Microarray-based expression
proﬁling is a powerful approach for the investigation of complex clinical conditions such as sepsis. In this study,
we investigated whole-genome expression proﬁles in mononuclear cells from septic patients admitted in inten-
sive care units with community-acquired pneumonia. Blood samples were collected at the time of sepsis diagno-
sis and seven days later since we aimed to evaluate the role of biological processes or genes possibly involved in
patient recovery. Here we provide a detailed description of the study design, including clinical information, ex-
perimental methods and procedures regarding data analysis. Metadata corresponding to microarray results de-
posited in the database Gene Expression Omnibus (GEO) under the accession number GSE48080 are also
described in this report. Our dataset allows the identiﬁcation of genes possibly associated with host defense to
infection as well as gene expression patterns associated with patient outcome.
© 2014 The Authors. Published by Elsevier Inc. This is an open access article under the CC BY-NC-SA license
(http://creativecommons.org/licenses/by-nc-sa/3.0/).(SpeciﬁcationsOrganism/cell
line/tissueHomo sapiensSex Male and female
Sequencer or
array typeAgilent Whole Human Genome
Microarray 4 × 44K arrays G4112FData format Background-corrected signals
Experimental
factorsSamples were peripheral blood mononuclear cells from
patients with sepsis secondary to community-acquired
pneumoniaExperimental
featuresGene expression proﬁling comparing peripheral blood
mononuclear cells from healthy volunteers and septic patients.
Samples from septic patients were collected at two time points:
D0 [within 48 h of the ﬁrst occurrence of organ dysfunction
indicative of severe sepsis or septic shock] and D7 [seven days
after the ﬁrst sample was collected]. Results compared healthy
individuals with patients, and survivor and non-survivor
septic patients.ino).
. This is an open access article under thcontinued)
SpeciﬁcationsConsente CC BY-NC-SA liceWritten informed consent was obtained from
all participants or, when necessary,
from relatives before enrollment in the study protocol.Sample source
locationIntensive care units from Sao Paulo Hospital,
Albert Einstein and Sirio Libanes Hospital, Sao Paulo, BrazilDirect link to deposited data
Deposited data can be found at http://www.ncbi.nlm.nih.gov/geo/
query/acc.cgi?acc=GSE48080.
Materials and methods
Experimental design
We investigated whole-genome gene expression proﬁles of periph-
eral bloodmononuclear cells from survivors and non-survivors of sepsisnse (http://creativecommons.org/licenses/by-nc-sa/3.0/).
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time of sepsis diagnosis and seven days later, allowing us to evaluate the
role of biological processes or genes that may be involved in patient re-
covery. Aiming to at least partially circumvent the heterogeneity of sep-
tic patient populations, we included only patients admitted with sepsis
caused by community-acquired pneumonia. However, patients varied
in SOFA and APACHEII scores.Patients and healthy volunteers
A total of ten severe sepsis or septic shock patients and three healthy
volunteers were included in this study. Five patients were admitted
with severe sepsis and ﬁve with septic shock (Table 1). Sepsis is a sys-
temic inﬂammatory response secondary to an infection and its mecha-
nisms have been shown to be complex and dynamic [1,2]. Severe
sepsis is sepsis complicated by acute organ dysfunction, and septic
shock includes either hypotension that is refractory to ﬂuid resuscita-
tion or hyperlactatemia [3]. Severe sepsis may occur as a result of
community-acquired and health care-associated infections but these
particular conditions may require speciﬁc treatment approaches and
clinical ormolecularmarkersmay differ [4]. Thus, as ameans to circum-
vent variability in the results, all patients included in this study were
adults with community-acquired, radiologically conﬁrmed, pneumonia
(CAP) as the primary source of infection. Reportedly, the most frequent
etiological agent in CAP is Streptococcus pneumonia [5,6] but we have
not had access to the etiological agent for all our patients and, therefore,
could not include this data in the analysis. Patients were divided into
two groups: patients that either succumbed to or survived their sepsis
episode. Their age ranged from 25 to 92 years. Patients were enrolled
within 48 h of the ﬁrst occurrence of organ dysfunction indicative of se-
vere sepsis. APACHE II scores (Acute Physiology and Chronic Health
Evaluation II) [7] ranged from 7 to 23, and SOFA scores (Sequential
Organ Failure Assessment score) [8] ranged from 2 to 11 at enrollment.
Both systems classify severity of the disease and are usually applied
within 24 h of admission of the patient in the ICU. We also included as
a variable the administration of vasopressors (i.e. drugs that induce va-
soconstriction, elevatingmean arterial pressure when septic shock per-
sists despite ﬂuid resuscitation) since we assumed this could inﬂuence
our gene expression results. Healthy controls, two females and one
male, were 36, 58 and 84 years old, and were included in the study so
we could evaluate gene expression patterns characterizing septic
patients. Exclusion criteria were: individuals under 18 years old,
patients with immunosuppressive therapy, AIDS or end stage chronic
illness, and patients who had been submitted to any kind of experimen-
tal therapy. This study was approved by the ethics committees of the
participating hospitals (Sao Paulo Hospital 1477/06, Albert Einstein
Hospital 07/549, and Sirio Libanes Hospital 2006/27) and writtenTable 1
Demographic data and outcomes from severe sepsis and septic shock patients.
Patients Age
[years]
Status at
admission
Vasopressors APACHE
II
SOFA Outcome
P107 82 Septic shock Yes 23 6 Alive
P140 47 Severe sepsis Yes 16 11 Alive
P143 71 Severe sepsis No 10 3 Alive
P146 57 Septic shock Yes 14 10 Dead
P217 83 Severe sepsis No 14 4 Dead
P227 92 Septic shock Yes 12 10 Dead
P229 32 Severe sepsis No 7 7 Alive
P239 84 Septic shock Yes 19 9 Dead
P254 58 Septic shock Yes 23 9 Dead
P260 25 Severe sepsis No 15 2 Alive
Acute Physiology andChronic Health Evaluation II; SOFA: Sequential Organ Failure Assess-
ment score; Vasopressors: drugs that induce vasoconstriction.informed consent was obtained from all participants or, when neces-
sary, from relatives before enrollment in the study protocol.
Isolation of peripheral mononuclear cells and RNA extraction
Fifty milliliters of blood was collected in sodium heparin-treated
tubes (BD Biosciences, Franklin Lakes, NJ, USA) from healthy volunteers
and septic patients. Samples from septic patients were collected within
48 h of the ﬁrst occurrence of organ dysfunction indicative of severe
sepsis or septic shock (D0) and seven days after the ﬁrst sample was
collected (D7). Peripheral blood mononuclear cells were obtained
using the Ficoll gradient method (Ficoll-Paque PLUS, GE Healthcare
Life Sciences, Uppsala, Sweden). Cells were frozen in fetal bovine
serum (Gibco, Life Technologies, USA) with 10% dimethyl sulfoxide
(Calbiochem, La Jolla, CA, USA) and stored in liquid nitrogen until
required for RNA extraction. The standard cell concentration was
1 × 107 cells/mL. Total RNAwas isolated from peripheralmononuclear
cells using Illustra RNAspin Mini Kit (GE Healthcare Life Sciences). The
quality and concentration of the RNA were determined using an RNA
Nano Chip Kit and a 2100 Bioanalyzer (Agilent Technologies, Santa
Clara, CA, USA). RNA purity (ratio of absorbance at 260 nm and 280 nm)
was accessed using the NanoVue spectrophotometer (GE Healthcare Life
Sciences). Only samples presenting suitable RNA integrity number
(RIN ≥ 7) and RNA purity (A260/280 ~ 2) were used for gene expression
proﬁling.
Gene expression proﬁling using DNA microarrays
Microarray analysis was performed using Agilent Whole Human
Genome Microarray 4 × 44K arrays (design ID 014850). This array is
manufactured using the 60-mer SurePrint Agilent technology and its
format targets 19,596 Entrez Gene RNAs. For the gene list, annotation
and probe sequences one should visit eArray application at http://
www.genomics.agilent.com. Labeling of probes with cyanine 3 dye
(Cy3), hybridization and washing procedures followed, strictly, the
manufacturer's protocol (One Color Quick Amp Labeling Kit, Agilent
Technologies). The arrays were scanned using a GenePix 4000B Micro-
array Scanner (Molecular Devices) using default parameters for Agilent
44K microarrays. Initial data analysis was performed using the Agilent
Feature Extraction software (version 9.5). This software places the mi-
croarray grids, determines feature intensities and ﬂags outlier pixels.
The quality of the microarray data was assessed using the positive con-
trols and RNA spike-ins. The gProcessedSignal (i.e. end result of stan-
dard Agilent Feature Extraction normalization and background
correction procedures) from each array was loaded into the Partek Ge-
nomics Suite (v6.6), normalized between arrays using quantile normal-
ization, and log transformed for further analyses. Principal Components
Analysis (PCA) was used as an exploratory tool to identify major effects
inﬂuencing data. One could say that the PCA plot reveals the structure of
the data in a way that best explains its variance, allowing us to visualize
themultivariate dataset [i.e. our gene expression values per sample] as a
lower-dimensional picture. The ﬁnal result can be described as a projec-
tion of the data, viewed from itsmost informative viewpoint. In our study
this approach allowed for the identiﬁcation of gene expression patterns
associatedwith sepsis, when comparisonsweremade between septic pa-
tients and healthy volunteers, and with patient outcome when we com-
pared survivors and non-survivors.
For subsequent statistical analysis we used the ANOVA implementa-
tion of Partek. The ANOVA model was deﬁned by the experimental de-
sign and included variations due to volunteer group (sepsis, control),
day of sample collection (D0, D7) and survival status (survivor, non-
survivor). Since RNA extraction was not performed in the same day,
we also used the analysis of variance to remove possible batch effects.
Gene expression patterns related to biological function were assessed
using Gene Ontology (GO) term enrichment analysis and KEGG
pathway mapping through DAVID Bioinformatics Resources 6.7
334 P. Severino et al. / Genomics Data 2 (2014) 332–334(http://david.abcc.ncifcrf.gov). For the identiﬁcation of differentially
expressed genes we took in consideration the characteristics of each
experiment for determining a cut-off and, therefore, the cut-off varied
depending on the studied group. The raw microarray data
(background-corrected signal) can be assessed at Gene Expression
Omnibus (GEO accession GSE48080).Competing interests
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